Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Zenotech Lab.
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 10.98 | 9.26 | 11.53 | 10.94 | 9.11 | 9.91 | 9.77 | 11.24 | 12.13 | 9.64 | 11.23 | 12.86 | 9.89 |
| Expenses + | 5.95 | 5.59 | 6.01 | 5.67 | 6.33 | 6.48 | 7.36 | 7.37 | 7.66 | 7.18 | 8.94 | 8.59 | 9.72 |
| Operating Profit | 5.03 | 3.67 | 5.52 | 5.27 | 2.78 | 3.43 | 2.41 | 3.87 | 4.47 | 2.46 | 2.29 | 4.27 | 0.17 |
| OPM % | 45.81% | 39.63% | 47.88% | 48.17% | 30.52% | 34.61% | 24.67% | 34.43% | 36.85% | 25.52% | 20.39% | 33.20% | 1.72% |
| Other Income + | 0.23 | 0.20 | 0.19 | 0.28 | 0.33 | 0.34 | 1.69 | 1.00 | 0.44 | 0.59 | 0.75 | 0.12 | 0.65 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 1.78 | 1.80 | 1.81 | 1.74 | 1.73 | 1.73 | 1.75 | 1.76 | 1.73 | 1.77 | 1.78 | 1.80 | 1.76 |
| Profit before tax | 3.48 | 2.07 | 3.90 | 3.81 | 1.38 | 2.04 | 2.35 | 3.11 | 3.18 | 1.28 | 1.26 | 2.59 | -0.94 |
| Tax % | -5.17% | 29.95% | 27.18% | 11.55% | 51.45% | 37.25% | 42.55% | 45.66% | 61.32% | 22.66% | 165.87% | 25.48% | 235.11% |
| Net Profit + | 3.67 | 1.44 | 2.83 | 3.36 | 0.66 | 1.29 | 1.35 | 1.69 | 1.23 | 0.99 | -0.84 | 1.93 | -3.15 |
| EPS in Rs | 0.60 | 0.24 | 0.46 | 0.55 | 0.11 | 0.21 | 0.22 | 0.28 | 0.20 | 0.16 | -0.14 | 0.32 | -0.52 |
Financials of Zenotech Lab.
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 4.08 | 2.06 | 2.25 | 11.14 | 13.03 | 26.02 | 22.45 | 36.57 | 42.42 | 40.83 | 43.05 | 43.61 |
| Expenses + | 24.14 | 9.73 | 12.65 | 19.01 | 16.54 | 17.04 | 16.07 | 19.11 | 21.71 | 23.56 | 28.87 | 34.42 |
| Operating Profit | -20.06 | -7.67 | -10.40 | -7.87 | -3.51 | 8.98 | 6.38 | 17.46 | 20.71 | 17.27 | 14.18 | 9.19 |
| OPM % | -491.67% | -372.33% | -462.22% | -70.65% | -26.94% | 34.51% | 28.42% | 47.74% | 48.82% | 42.30% | 32.94% | 21.07% |
| Other Income + | 0.35 | 0.04 | 1.91 | 2.37 | 4.71 | 7.54 | 0.41 | 0.63 | 1.08 | 0.96 | 3.47 | 2.11 |
| Interest | 6.65 | 7.55 | 7.50 | 2.45 | 0.12 | 0.89 | 1.55 | 1.22 | 0.11 | 0.00 | 0.00 | 0.00 |
| Depreciation | 4.06 | 3.96 | 3.87 | 3.90 | 4.20 | 4.85 | 6.46 | 6.97 | 7.17 | 7.09 | 6.96 | 7.11 |
| Profit before tax | -30.42 | -19.14 | -19.86 | -11.85 | -3.12 | 10.78 | -1.22 | 9.90 | 14.51 | 11.14 | 10.69 | 4.19 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -123.94% | 20.12% | 25.49% | 47.52% | 125.54% |
| Net Profit + | -30.41 | -19.14 | -19.87 | -11.85 | -3.13 | 10.78 | -1.22 | 22.18 | 11.59 | 8.30 | 5.61 | -1.07 |
| EPS in Rs | -4.99 | -3.14 | -3.26 | -1.94 | -0.51 | 1.77 | -0.20 | 3.63 | 1.90 | 1.36 | 0.92 | -0.18 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials of Zenotech Lab.
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 34.43 | 34.43 | 34.43 | 61.03 | 61.03 | 61.03 | 61.03 | 61.03 | 61.03 | 61.03 | 61.03 | 61.03 |
| Reserves | -61.68 | -80.49 | -100.33 | -19.01 | -22.13 | -11.40 | -12.62 | 9.61 | 21.24 | 29.51 | 35.10 | 34.09 |
| Borrowings + | 54.32 | 54.29 | 54.28 | 0.00 | 20.24 | 21.42 | 20.66 | 6.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities + | 36.64 | 44.69 | 62.37 | 39.72 | 25.45 | 14.51 | 16.78 | 17.45 | 18.61 | 15.66 | 14.90 | 16.03 |
| Total Liabilities | 63.71 | 52.92 | 50.75 | 81.74 | 84.59 | 85.56 | 85.85 | 94.09 | 100.88 | 106.20 | 111.03 | 111.15 |
| Fixed Assets + | 52.13 | 48.17 | 46.83 | 44.43 | 43.11 | 48.73 | 74.23 | 70.91 | 65.38 | 65.58 | 60.87 | 62.29 |
| CWIP | 0.00 | 0.00 | 0.00 | 2.32 | 16.95 | 29.08 | 2.18 | 0.28 | 4.98 | 1.96 | 3.57 | 3.60 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets + | 11.58 | 4.75 | 3.92 | 34.99 | 24.53 | 7.75 | 9.44 | 22.90 | 30.52 | 38.66 | 46.59 | 45.26 |
| Total Assets | 63.71 | 52.92 | 50.75 | 81.74 | 84.59 | 85.56 | 85.85 | 94.09 | 100.88 | 106.20 | 111.03 | 111.15 |
Financials of Zenotech Lab.
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -7.72 | -4.80 | 1.64 | -16.25 | -14.04 | 11.38 | 5.74 | 17.67 | 20.66 | 11.82 | 9.49 | 10.20 |
| Cash from Investing Activity + | 0.34 | 5.50 | -0.69 | -2.65 | -16.19 | -20.79 | -4.82 | -1.84 | -5.82 | -21.15 | 15.27 | -6.49 |
| Cash from Financing Activity + | 6.77 | -0.83 | -0.72 | 46.83 | 15.02 | -2.70 | 0.45 | -15.87 | -6.11 | 0.00 | 0.00 | 0.00 |
| Net Cash Flow | -0.60 | -0.13 | 0.23 | 27.92 | -15.21 | -12.11 | 1.38 | -0.04 | 8.73 | -9.33 | 24.76 | 3.71 |
| Free Cash Flow | -7.75 | -4.81 | 0.93 | -20.07 | -32.07 | -10.37 | 0.83 | 15.73 | 14.47 | 7.59 | 5.63 | 1.88 |
| CFO/OP | 38% | 76% | -15% | 203% | 387% | 130% | 92% | 107% | 106% | 75% | 81% | 105% |
Financials of Zenotech Lab.
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 35.78 | 62.01 | 0.00 | 0.00 | 66.11 | 26.09 | 61.78 | 39.22 | 28.57 | 29.05 | 63.16 | 73.49 |
| Inventory Days | 232.69 | 305.45 | 202.29 | 374.12 | 294.03 | |||||||
| Days Payable | 222.42 | 816.45 | 1,127.98 | 2,468.31 | 2,088.61 | |||||||
| Cash Conversion Cycle | 46.05 | -448.99 | -925.69 | -2,094.19 | -1,728.47 | 26.09 | 61.78 | 39.22 | 28.57 | 29.05 | 63.16 | 73.49 |
| Working Capital Days | -7,875.23 | -17,133.74 | -18,700.98 | -1,218.52 | -1,103.96 | -432.75 | -163.56 | -106.00 | -98.86 | -62.93 | -27.98 | -12.05 |
| ROCE % | -61.54% | -65.67% | -61.84% | -5.93% | 8.14% | 0.47% | 15.26% | 18.35% | 12.94% | 9.40% | 4.59% |
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…